References

1. Infusion Nurses Society. Infusion Nursing Standards of Practice. J Infus Nurs. 2006;29(1S).
2. Polovich M, White J, Kelleher L, eds. Chemotherapy and Biotherapy Guidelines and Recommendations for Practice. 2nd ed. Pittsburgh, PA: Oncology Nursing Society; 2005.
3. Infusion Nurses Society. Flushing Protocols. Norwood, MA: Infusion Nurses Society; 2008.
4. Stern R, Pittman S, Doershuk C, Matthews L. Use of a "heparin lock" in the intermittent administration of intravenous drugs: A technical adcance in intravenous therapy. Clin Pediatr. 1972;11(9):521-523.
5. Goldberger J, DeLuca F, Wesselhoeft C, Randall H. A home program of long-term total parenteral nutrition in children. J Pediatr. 1979;94(2):325-328.
6. Stiver H, Telford G, Mossey J, et al. Intravenous antibiotic therapy at home. Ann Int Med. 1978;89(5):690-693.
7. Hirsh J, Raschke R. Heparin and low-molecular weight heparin: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest. 2004;126(3):188S-203S.
8. Kimura E, Darby T, Krause R, Brondyk H. Parenteral toxicity studies with benzyl alcohol. Toxicol Appl Pharmacol. 1971;18:60-68.
9. Gahart B, Nazazreno A. Intravenous Medications. 24th ed. St. Louis: Mosby/Elsevier; 2008.
10. Hadaway L. Flushing vascular access catheters: risk for infection transmission. Infect Control Res. 2007;4(2):1-8.
11. Association for Practitioners in Infection Control. APIC Position Paper: Safe injection, infusion, and medication vial practices in healthcare. http://www.apic.org/Content/NavigationMenu/Government Advocacy/PublicPolicyLibrary/SafeInjections_final.pdf. Accessed July 26, 2010.
12. Goode C, Titler M, Rakel B, et al. A meta-analysis of effects of heparin flush and saline flush: quality and cost implications. Nurs Res. 1991;40(6):324-330.
13. Peterson F, Kirchhoff K. Analysis of the research about heparinized versus nonheparinized intravenous lines. Heart Lung. 1991;20(6):631-640.
14. Mayo D, Horne M, Summers B, Pearson D, Helsabeck C. The effects of heparin flush on patency of Groshong catheter: a pilot study. Oncol Nurs Forum. 1996;23(9):1401-1405.
15. Hoffer E, Borse J, Santulli P, Bloch R, Fonteine A. Prospective randomized comparison of valved versus nonvalved peripherally inserted central vein catheters. Am J Roentgen. 1999;173:1393-1398.
16. Andersen K, Holland J. Maintaining the patency of peripherally inserted central catheters with 10 units /cc heparin. J Intraven Nurs. 1992;15(2):84-88.
17. Stephens L, Haire W, Tarantolo S, et al. Normal saline versus heparin flush for maintaining central venous catheter patency during apheresis collection of peripheral blood stem cells (PBSC). Transfus Sci. 1997;18(2):187-193.
18. Buswell L, Beyea S. Flushing protocols for tunneled central venous catheters: an integrative review of the literature. Online J Knowl Synth Nurs. 1998;5(3).
19. Lersch C, Lotowa W, Fung S, Jansses D. Prophylaxis of port system-assocaited thromboses in adcanced oncology patients using heparin flushing. J Cancer Res Clin Oncol. 2004;130(4):235-241.
20. DeNeef M, Heijboer H, Woensel JV, DeHaan R. The efficacy of heparinzation in prolonging patency of arterial and central venous catheters in children: a randomized double-blind trial. Pediatr Hematol Oncol. 2002;19(8):553-560.
21. Randolph A, Cook D, Gonzales C, Andrew M. Benefit of heparin in central venous and pulmonary artery catheters: a meta-analysis of randomized controlled trials. Chest. 1998;113(1):165-171.
22. Jacobs B, Schilling S, Doellman D, Hutchinson N, Rickey M, Nelson S. Central venous catheters occlusion: a prospective, controlled trial examing the impact of a positive-pressure valve device. J Parenter Enteral Nutr. 2004;28(2):113-118.
23. Schilling S, Doellman D, Hutchinson N, Jacobs B. The impact of needleless connector device design on central venous catheter occlusion in children: a prospective controlled trial. J Parenter Enteral Nutr. 2006;30(2):85-90.
24. Bowers L, Speroni K, Jones L, Atherton M. Comparison of occlusion rates by flushing solutions for peripherally inserted central catheters with positive pressure luer-activated devices. J Infus Nursing. 2008;31(1):22-27.
25. Cesaro S, Tridello G, Cavaliere M, et al. Prospective, randomized trial of two different modalities of flushing central venous catheters in pediatric patients with cancer. J Clin Oncol. 2009;27(12):2059-2065.
26. ASHP. Policy Recommendation: The Safey and Effective Use of Heparin in Neonatal Patients. Bethesda, MD: American Society of Health-System Pharmacists; 2009.
27. Institute for Vaccine Safety, Johns Hopkins Bloomberg School of Public Health. Religious leaders approval of use of vaccines containing porcine gelatin. http://www.vaccinesafety.edu/Porcine-vaccineapproval.htm. Accessed July 26, 2010.
28. Karaaslan H, Peyronnet P, Benevent D, Lagarde C, Rince M, Leroux-Robert C. Risk of heparin lock-related bleeding when using indwelling venous catheter in haemodialysis. Nephrol Dial Transplant. 2001;16(10):2072-2074.
29. Vorweg M, Monaca E, Doehn M, Wappler F. The "heparin lock": cause for iatrogenic coagulopathy. Eur J Anesthesiol. 2006;23(1):50-53.
30. Sombolos K, Fragia T, Bamichas G, et al. Heparin solutions locked in acute hemodialysis
    catheters: Impact on activated partial thromboplastin time. ASAIO J. 2003;49(3):287-289.
31. Moran JE, Ash SR. Locking solutions for hemodialysis catheters; heparin and citrate—a position paper by ASDIN. Semin Dial. 2008;21(5):490-492.
32. Pinto K. Accuracy of coagulation values obtained fron a heparinized central venous catheter. Oncol Nursing Forum. 1994;21(3):573-575.
33. Mayo DJ, Dimond EP, Kramer W, McDonald KH. Discard volumes necessary for clinically useful coagulation studies from heparinized Hickman catheters. Oncol Nursing Forum. 1996;23(4):671-675.
34. Hinds P, Quargnenti A, Gattuso J, Srivastava D. Comparing the results of coagulation tests on blood drawn by venipuncture and through heparinized tunneled venous access devices in pediatric patients with cancer. Oncology Nurs Forum. 2002;29(3)E26-E34.
35. Trissel L. Handbook on Injectable Drugs. 12th ed. Bethesda, MD: American Society of Health-System Pharmacists; 2003.
36. Rosett W, Hodges G. Antimicrobial activity of heparin. J Clin Microbiol. 1980;11(1):30-34.
37. Randolph A, Cook D, Gonzales C, Andrew M. Benefit of heparin in peripheral venous and arterial catheters: systematic review and meta-analysis of randomised controlled trials. BMJ. 1998;316(7136):969-975.
38. Shanks R, Donegan N, Graver M, et al. Heparin stimulates Staphylococcus aureus biofilm formation. Infect Immun. 2005;73(8):4596-4606.
39. Shanks R, Sargent J, Martinez R, Graber M, O'Toole G. Catheter lock solutions influence staphylococcal biofilm formation on abiotic surfaces. Nephrol Dial Transplant. 2006;21(8):2247-2255.
40. Update: Delayed onset of Pseudomonas fluorescens bloodstream infections after exposure to contaminated heparin flush—Michigan and South Dakota, 2005-2006. MMWR Morb Mortal Weekly Rep. 2006;55(35):961-963.
41. Souza Dias MB, Habert AB, Borrasca V, et al. Salvage of long-term central venous catheters during an outbreak of Pseudomonas putida and Stenotrophomonas maltophilia infections associated with contaminated heparin catheter-lock solution. Infect Control Hosp Epidemiol. 2008;29(2):125-130.
42. Markota I, Markota D, Tomic M. Measuring of the heparin leakage into the circulation from central venous catheters—an in vivo study. Nephrol Dial Transplant. 2009;24(5):1550-1553.
43. Warkentin T, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention. Chest. 2004;126(3):311S-337S.
44. Warkentin TE, Greinacher A, Koster A, Lincoff AM. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 suppl):340S-380S.
45. Kadidal V, Mayo D, Horne M. Heparin-induced thrombocytopenia (HIT) due to heparin flushes: a report of three cases. J Int Med. 1999;246(3):325-329.
46. Gettings E, Brush K, Cott EV, Hurford W. Outcome of postoperative critically ill patients with heparin-induced thrombocytopenia: an observational retrospective case-control study. Crit Care. 2006;10(6):R161-168.
47. Ranze O, Rakow A, Ranze P, Eichler P. Low-dose danaparoid sodium catheter flushes in an intensive care infant suffering from heparin-induced thrombocytopenia. Pediatr Crit Care Med. 2001;2(2):175-177.
48. Dai M, Hsieh A, Chao T. Catastrophic heparin-induced thronbocytopenia/thrombosis syndrome related to the use of a Port-A-Cath in a breast cancer patient receiving chemotherapy. Support Care Cancer. 2004;12(7):537-539.
49. Muslimani A, Ricaurte B, Daw H. Immune heparin-induced thrombocytopenia resulting from preceding exposure to heparin catheter flushes. Am J Hematol. 2007;82(7):652-655.
50. Laster J, Silver D. Heparin-coated catheters and heparin-induced thrombocytopenia. J Vasc Surg. 1988;7(5):677-672.
51. McNulty I, Katz E, Kim KY. Thrombocytopenia following heparin flush. Prog Cardiovasc Nurs. 2005;20(4):143-147.
52. Heparin errors continue despite prior, high-profile, fatal events. Institute for Safe Medications Practices Web site. http://www.ismp.org/Newsletters/acutecare/articles/20080717.asp. Accessed June 15, 2009, 2009.
53. There's more to the 60 Minutes story on heparin errors. Institute for Safe Medications Practices Web site. http://www.ismp.org/Newsletters/acutecare/articles/20080327.asp. Accessed June 15, 2009.
54. ]Action needed to prevent dangerous heparin-insulin confusion. Institute for Safe Medications Practices Web site. http://www.ismp.org/Newsletters/acutecare/articles/20070503.asp. Accessed June 15, 2009.
55. Silini E, Locasciulli A, Santoleri L, et al. Hepatitis C virus infection in a hematology ward: evidence for nosocomial transmission and impact on hematologic disease outcome. Haematologica. 2002;87(11):1200-1208.
56. Kokubo S, Horii T, Yonekawa O, Ozawa N, Mukaide M. A phylogenetic-tree analysis elucidating nosocomial transmission of hepatitis C virus in a haemodialysis unit. J Viral Hepatol. 2002;9(6):450-454.
57. Widell A, Christensson B, Wiebe T, et al. Epidemiologic and molecular investigation of outbreaks of hepatitis C virus infection on a pediatric oncology service. Ann Intern Med. 1999;130(2):130-134.
58. Lagging L, Aneman C, Nenonen N, et al. Nosocomial transmission of HCV in a cardiology ward during the window phase of infection: an epidemiological and molecular investigation. Scand J Infect Dis. 2002;34(8):580-582.
59. Krause G, Trepka M, Whisenhunt R, et al. Nosocomial transmission of hepatitis C virus associated with the use of multidose saline vials. Infect Control Hosp Epidemiol. 2003;24(2):122-127.
60. Abulrahi H, Bohlega E, Fontaine R, Al-Seghayer S, Al-Ruwais A. Plasmodium falciparum malaria transmitted in hospital through heparin locks. Lancet. 1997;349(9044):23-25.
61. Katzenstein T, Jorgensen L, Permin H, et al. Nosocomial HIV-trasmission in an outpatient clinic detected by epidemiological and phylogenetic analyses. AIDS. 1999;13(13):1737-1744.
62. Santolucito JB. A retrospective evaluation of the timeliness of physician-initiated PICC referrals. J Vasc Access Devices. 2001;6(3):20-26.
63. Raad I, Chatzinikolaou I, Chaiban G, et al. In vitro and ex vivo activities of minocycline and EDTA against microorganisms embedded in biofilm on catheter surfaces. Antimicrob Agents Chemother. 2003;47(11):3580-3585.
64. Raad I, Hachem R, Tcholakian R, Sheretz R. Efficacy of minocycline and EDTA lock solution in preventing catheter-related bacteremia, septic phlebitis, and endocarditis in rabbits. Antimicrob Agents Chemother. 2002;46(2):327-332.
65. Kite P, Eastwood K, Sugden S, Percival S. Use of in vivo-generated biofilms from hemodialysis catheters to test the efficacy of a novel antimicrobial catheter lock for biofilm eradication in vitro. J Clin Microbiol. 2004;42(7):3073-3076.
66. Percival S, Kite P, Eastwood K, et al. Tetrasodium EDTA as a novel central venous catheter lock solutions against biofilm. Infect Control Hosp Epidemiol. 2005;26(6):515-519.
67. Sheretz R, Boger M, Collins C, Mason L, Raad I. Comparative in vitro efficacies of various catheter lock solutions. Antimicrob Agents Chemother. 2006;50(5):1865-1868.
68. Crnich CJ, Halfmann JA, Crone WC, Maki DG. The effects of prolonged ethanol exposure on the mechanical properties of polyurethane and silicone catheters used for intravenous access. Infect Control Hosp Epidemiol. 2005;26(8):708-714.
69. Chambers ST, Pithie A, Gallagher K, Liu T, Charles CJ, Seaward L. Treatment of Staphylococcus epidermidis central vascular catheter infection with 70% ethanol locks: efficacy in a sheep model. J Antimicrob Chemother. 2007;59(4):779-782.
70. Sanders J, Pithie A, Ganly P, et al. A prospective double-blind randomized trial comparing intraluminal ethanol with heparinized saline for the prevention of catheter-associated bloodstream infection in immunosuppressed haematology patients. J Antimicrob Chemother. 2008;62(4):809-815.
71. Winnett G, Nolan J, Miller M, Ashman N. Trisodium citrate 46.7% selectively and safely reduces staphylococcal catheter-related bacteraemia. Nephrol Dial Transplant. 2008;23(12):4075.
72. Rioux JP, De Bortoli B, Troyanov S, Madore F. The effect of sodium citrate 4% locking solution for central venous dialysis catheter on the international normalized ratio (INR) value. Nephrol Dial Transplant. 2008;23(5):1772-1773; author reply 1773.
73. Grudzinski L, Quinan P, Kwok S, Peirratos A. Sodium citrate 4% locking solution for central venous dialysis catheters—an effective, more cost-efficient alternative to heparin. Nephrol Dial Transplant. 2007;22(2):471-476.
74. Weijmer MC, van den Dorpel MA, Van de Ven PJ, et al. Randomized, clinical trial comparison of trisodium citrate 30% and heparin as a catheter-locking solution in hemodialysis patients. J Am Soc Nephrol. 2005;16(9):2769-2777.
75. Weijmer M, Debets-Ossenkopp YJ, Van De Vondervoort FJ, ter Wee PM. Superior antimicrobial activity of trisodium citrate over heparin for catheter locking. Nephrol Dial Transplant. 2002;17(6):2189-2195.
76. Simon A, Ammann RA, Wiszniewsky G, Bode U, Fleischhack G, Besuden MM. Taurolidine-citrate lock solution (TauroLock) significantly reduces CVAD-associated grampositive infections in pediatric cancer patients. BMC Infect Dis. 2008;8:102.
77. Bell AL, Jayaraman R, Vercaigne LM. Effect of ethanol/trisodium citrate lock on the mechanical properties of carbothane hemodialysis catheters. Clin Nephrol. 2006;65(5):342-348.
78. Takla TA, Zelenitsky SA, Vercaigne LM. Effectiveness of a 30% ethanol/4% trisodium citrate locking solution in preventing biofilm formation by organisms causing haemodialysis catheter-related infections. J Antimicrob Chemother. 2008;62(5):1024-1026.
79. Steczko J, Ash SR, Nivens DE, Brewer L, Winger RK. Microbial inactivation properties of a new antimicrobial/antithrombotic catheter lock solution (citrate/methylene blue/parabens). Nephrol Dial Transplant. 2009;24(4)1937-1945.
80. McGill RL, Spero JA, Sysak JC, Sandroni SE, Marcus RJ. Tissue plasminogen activator as a hemodialysis catheter locking solution. Hemodial Int. 2008;12(3):348-351.
81. Schenk P, Rosenkranz A, Wolfl G, Horl W, Traindl O. Recombinant tissue plasminogen activator is a useful alternative heprin in priming Quinton Permcath. Am Kidney Dis. 2000;35(1):130-136.
82. Horne M, McCloskey D, Calis K, Wesley R, Childs R, Kasten-Sportes C. Use of heparin versus lepirudin flushes to prevent withdrawal occlusion of central venous access devices. Pharmacotherapy. 2006;26(9):1262-1267.
83. Kethireddy S, Safdar N. Urokinase lock or flush solution for prevention of bloodstream infections associated with central venous catheters for chemotherapy: a meta-analysis of prospective randomized trials. J Vasc Access. 2008;9(1):51-57.